You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Interactive technology for media literacy drug prevention in community groups

    SBC: REAL PREVENTION LLC            Topic: NIDA

    The goals of this Phase II STTR are to evaluate the outcomes of REAL mediaan interactiveselfpacede learning substance use prevention media literacy curriculum and prepare it for marketing to community organizationsincluding our partnerHSubstance use increases in frequency and risk through mid adolescenceyet prevention interventions primarily target early useare time intensiveand are implemented in ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  2. A Novel Scaffold to Promote Skin Regeneration

    SBC: FirstString Research, Inc            Topic: NIAMS

    PROJECT SUMMARY Dermal scarring affects more than million people worldwide annually over million people are injured in motor vehicle accidents over million patients are severely burned and thousands of warriors are wounded in military blasts In severe burns more than of patients develop hypertrophic scar contraction which leads to hypertrophic scar contractures HSc HSc a ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Telehealth Intervention for Improved Blood Pressure Control with Targeted Incentives Using New Technologies and Insights From Behavioral Economics to Increase the Effectiveness of Behavioral Change

    SBC: Wellth Inc.            Topic: NIA

    PROJECT SUMMARY ABSTRACT Hypertension or sustained systolic and diastolic blood pressure BP of and mm Hg or higher is among the most frequently encountered conditions in primary care in the U S The estimated prevalence is among all U S adults and increases with age to affect of seniors Hypertension is also the leading risk factor for cardiovascular disease global mortality ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Polo box PLK Inhibitors Target Tumors Resistant to ATP Competitive Compounds

    SBC: PPI PHARMACEUTICALS, LLC            Topic: NCI

    Polo like kinase PLK is a central player in regulating entry into and progression through mitosis Many studies have validated PLK as an anti tumor drug target and its inhibition is potently anti proliferative to cancer cells However recent data suggests that there are two major disadvantages of the conventional approach to blocking the kinase activity of PLK First both general kinome ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Soluble E NTPDase for sepsis

    SBC: Purine Pharmaceuticals Inc.            Topic: NIGMS

    SUMMARY Sepsis is a medical condition caused by an overwhelming systemic inflammatory response to infection Although the underlying infection can now be efficiently treated with antibiotics there are no effective therapies to control the organ damage caused by the inflammatory response of the host As a result sepsis is the leading cause of mortality in intensive care units and is the tenth lea ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. A practical and versatile high resolution D dosimetry system for clinical use

    SBC: HEURIS INC.            Topic: 102

    Quality assurance QA is a critical component of radiation oncology that ensures both effective treatment delivery and patient safety Over the last decade dQA is now particularly important asramatic innovations in treatment delivery technologiesy have led to increasingly sophisticated and complex treatments that are difficult to adequately verify with conventional dosimetric verification system ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Small Molecule Therapy for the Treatment of Heart Failure

    SBC: SUMOCOR LLC            Topic: NHLBI

    ABSTRACT The incidence of heart failure HF continues to increase in the United States despite significant advances in pharmacological therapies and novel devices There is an acute need for novel treatment strategies for heart failure A key abnormality in HF is defective handling of calcium that has been partially related to abnormal sarcoplasmic reticulum SR function in cardiac myocytes Red ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Targeting B-cell lymphoma with Leukothera-phase II

    SBC: Actinobac Biomed, Inc.            Topic: NCI

    DESCRIPTION provided by applicant B cell lymphoma is cancer of B lymphocytes and accounts for more than deaths in the U S each year While many patients respond to currently available therapy there is a high rate of cancer relapse and inability for the patients o tolerate chemotherapy Thus there is a significant need to make available to these patients newer therapies that are more e ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  9. A Rapid assay for RNA targeted drugs: Instrumentation Supplement

    SBC: NUBAD LLC            Topic: 300

    DESCRIPTION provided by applicant Some of the most significant therapies that treat disease target nucleic acids Drugs that target nucleic acid include cancer drugs antibiotics and antivirals Combined these classes of drugs have annual sales worldwide of $ billion Antibiotics that target nucleic acids account for $ billion of the $ billion of sales annuall for all antibiotics an ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government